Adaptimmune Therapeutics (NASDAQ: ADAP) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Adaptimmune Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Earnings and Valuation

This table compares Adaptimmune Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Adaptimmune Therapeutics $14.20 million -$71.57 million -10.80
Adaptimmune Therapeutics Competitors $284.30 million $34.29 million 144.51

Adaptimmune Therapeutics’ competitors have higher revenue and earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Adaptimmune Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics 0 1 3 0 2.75
Adaptimmune Therapeutics Competitors 839 3190 11561 230 2.71

Adaptimmune Therapeutics currently has a consensus price target of $12.50, suggesting a potential upside of 54.32%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.65%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Adaptimmune Therapeutics is more favorable than its competitors.


This table compares Adaptimmune Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics -138.46% -27.99% -21.47%
Adaptimmune Therapeutics Competitors -5,263.56% -427.93% -38.66%

Insider and Institutional Ownership

71.8% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 24.5% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Adaptimmune Therapeutics beats its competitors on 8 of the 11 factors compared.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with's FREE daily email newsletter.